본문으로 건너뛰기
← 뒤로

The potential of plasma-derived medium-sized extracellular vesicles as a biopsy alternative for active surveillance decisions in prostate Cancer.

1/5 보강
Nanomedicine : nanotechnology, biology, and medicine 📖 저널 OA 0% 2025: 0/3 OA 2026: 0/19 OA 2025~2026 2025 Vol.67() p. 102828
Retraction 확인
출처

Szeliski K, Fekner Z, Kasiński D, Rasmus M, Kowalski F, Świtońska M, Sierakowska K, Drewa T, Pokrywczyńska M

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Diagnosing prostate cancer (PCa) and risk-stratifying patients remains challenging, as PSA-based methods lack precision for active surveillance (AS) decision-making.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Szeliski K, Fekner Z, et al. (2025). The potential of plasma-derived medium-sized extracellular vesicles as a biopsy alternative for active surveillance decisions in prostate Cancer.. Nanomedicine : nanotechnology, biology, and medicine, 67, 102828. https://doi.org/10.1016/j.nano.2025.102828
MLA Szeliski K, et al.. "The potential of plasma-derived medium-sized extracellular vesicles as a biopsy alternative for active surveillance decisions in prostate Cancer.." Nanomedicine : nanotechnology, biology, and medicine, vol. 67, 2025, pp. 102828.
PMID 40360098 ↗

Abstract

Diagnosing prostate cancer (PCa) and risk-stratifying patients remains challenging, as PSA-based methods lack precision for active surveillance (AS) decision-making. Extracellular vesicles (EVs) are membranous nano-sized vesicles released by all types of cells and may contain potentially interesting material for diagnostic procedures for PCa. This study analyzed surface markers and miRNA profiles of medium-sized plasma EVs (mEVs) from 24 PCa patients using nanoflow cytometry and miRNA profiling. The ratio of PSMA+ EVs to PSMA+CD9+ EVs differed significantly between AS and non-AS patients. Additionally, miR-99a-5p, miR-125b-5p, miR-145-5p, and miR-365a-3p levels were higher in non-AS patients. These findings suggest that plasma-derived PSMA+ mEVs originate from the prostate and may serve as biomarkers for PCa progression. Nanoflow cytometry-based analysis of EV surface markers combined with miRNA profiling provides a novel, non-invasive alternative to PSA measurements. This approach could improve risk stratification and decision-making for AS patients, potentially leading to better outcomes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반